Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of IndoVac (SARS-CoV-2 Protein Subunit Vaccine) in Indonesia
NCT05067894Phase 1Completed
- Sponsor
- Bio Farma
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IndoVac in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Bio Farma. Primary endpoint: Safety of the SARS-CoV-2 protein subunit recombinant vaccine within 7 days after each dose. Started Dec 2021; status: completed.
02
Drugs
IndoVac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05067894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067894.